Cell Source, Inc. CLCS OTC

Cell Source, Inc. (CLCS) generated $-748.33K in operating cash flow for quarter ending 2024-12-31. After capital expenditures of $4.00, free cash flow was $-748.33K.

Cash conversion ratio was 1.27x, indicating earnings are backed by cash.

Criteria supported by this page:

• HEALTH (0/100, Fail) — weak cash flow raises concerns about debt servicing
• MOAT (28/100, Fail) — limited free cash flow weakens the competitive position
• INCOME (?/100) — Cash conversion ratio was 1.27x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 17/100 with 0/7 criteria passed.